Literature DB >> 2513045

Immunotherapy of human cancers.

J R Hobbs1.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2513045      PMCID： PMC1838049          DOI： 10.1136/bmj.299.6709.1177

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.

Authors:  G Hale; M J Dyer; M R Clark; J M Phillips; R Marcus; L Riechmann; G Winter; H Waldmann
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

Review 2.  Outcome of displacement bone marrow transplantation for inborn errors of metabolism.

Authors:  J R Hobbs
Journal:  Acta Paediatr Jpn       Date:  1988-08

3.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

4.  Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy.

Authors:  R R Salup; T C Back; R H Wiltrout
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

5.  A clinical trial of anti-idiotype therapy for B cell malignancy.

Authors:  T C Meeker; J Lowder; D G Maloney; R A Miller; K Thielemans; R Warnke; R Levy
Journal:  Blood       Date:  1985-06       Impact factor: 22.113

6.  Clinical immunologic study of malignant disease: response to tumor transplants and transfer of leukocytes.

Authors:  S H Nadler; G E Moore
Journal:  Ann Surg       Date:  1966-09       Impact factor: 12.969

7.  A cytotoxic agent can be generated selectively at cancer sites.

Authors:  K D Bagshawe; C J Springer; F Searle; P Antoniw; S K Sharma; R G Melton; R F Sherwood
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640
  7 in total
  1 in total

Review 1.  Surgical excision alone is adequate treatment for primary colorectal cancer.

Authors:  R Hind; D R Rew; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1992-01       Impact factor: 1.891
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.